CompletedInterventionalPhase 2Last updated Jan 17, 2013

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors

Overview

ClinicalTrials.gov ID: NCT00025363
Lead Sponsor: National Cancer Institute (NCI)NIH
Brief Summary: Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
Study Type

Interventions

Drug: vincristine sulfateDrug: irinotecan hydrochlorideDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: tirapazamineBiological: filgrastimBiological: sargramostimOther: pharmacological studyOther: pharmacogenomic studiesOther: laboratory biomarker analysis

Status

Overall Status: Completed
Start Date: Nov 2001
Primary Completion Date: Oct 2007Actual
Completion Date: No data available

Study Record Dates

First Submitted: Oct 11, 2001
First Submitted that Met QC Criteria: Jan 26, 2003
First Posted: Jan 27, 2003Estimated
Last Update Submitted that Met QC Criteria: Jan 16, 2013
Last Update Posted: Jan 17, 2013Estimated
Last Verified: Jan 2013

NCT00354835Completed

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00003958Completed

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

NCT00077285Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

NCT07466316Recruiting

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

NCT00003955Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

NCT05457829Recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study